50 phenotypes from 2 alleles in 4 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd involves: 129S1/Sv * C57BL/6	abnormal apoptosis	J:68829
	abnormal cerebellar molecular layer	J:102702
	abnormal Leydig cell differentiation	J:68829
	abnormal lymph node medulla morphology	J:63299
	abnormal mammary gland epithelium morphology	J:63299
	abnormal neuron differentiation	J:102702
	abnormal neuronal migration	J:102702
	cortical renal glomerulopathies	J:63299
	decreased circulating testosterone level	J:68829
	decreased tumor-free survival time	J:63299
	enlarged lymph nodes	J:63299
	enlarged spleen	J:63299
	enlarged testis	J:68829
	increased B cell derived lymphoma incidence	J:63299
	increased body size	J:63299
	increased body weight	J:63299
	increased hemangiosarcoma incidence	J:63299
	increased Leydig cell number	J:68829
	increased pheochromocytoma incidence	J:63299
	increased pituitary adenoma incidence	J:63299
	increased renal carcinoma incidence	J:63299
	increased spleen white pulp amount	J:63299
	increased T cell derived lymphoma incidence	J:63299
	increased testis tumor incidence	J:63299
	kidney cortex cyst	J:63299
	kidney cyst	J:63299
	lymphoid hyperplasia	J:63299
	mammary gland hyperplasia	J:63299
	normal neoplasm	J:102702
	pituitary gland hyperplasia	J:63299
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi B6.129-Cdkn2ctm1Yxi	increased bronchioalveolar stem cell number	J:120835
	increased lung adenocarcinoma incidence	J:120835
	increased lung adenoma incidence	J:120835
	increased lung tumor incidence	J:120835
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi C.129-Cdkn2ctm1Yxi	abnormal mammary gland morphology	J:198018
	increased mammary gland tumor incidence	J:198018
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi involves: 129/Sv * C57BL/6 * DBA/2	abnormal pituitary intermediate lobe morphology	J:50053
	abnormal T cell physiology	J:50053
	abnormal thymus size	J:50053
	ataxia	J:50053
	dehydration	J:50053
	enlarged adrenal glands	J:50053
	enlarged pituitary gland	J:50053
	enlarged spleen	J:50053
	increased B cell number	J:50053
	increased body size	J:50053
	increased body weight	J:50053
	increased bone marrow cell number	J:50053
	increased pituitary adenoma incidence	J:50053
	increased T cell number	J:50053
	pituitary gland hyperplasia	J:50053
	small testis	J:50053
	spleen hyperplasia	J:50053
	thymus hyperplasia	J:50053
	weight loss	J:50053